Browse by Medical Category
Call to refer a patient or request an appointment:
Physicians in the Lung Radiofrequency Ablation Program in Massachusetts General Hospital's Division of Thoracic Surgery bring expertise in radiofrequency ablation (RFA) for patients with early-stage lung cancer who are deemed non-surgical candidates. Patients who choose Mass General for RFA receive specialized care at a world-renowned institution with an outstanding reputation.
Lung cancer is the most common cancer in the world and the leading cause of cancer-related death. At Mass General, we have a long tradition of treating this disease using both traditional methods and, more recently, minimally invasive techniques including:
Surgical removal remains the ideal approach for treating early-stage malignant non-small cell lung cancer (NSCLC). However, some patients may wish to avoid conventional surgery or, in some cases, may be too ill to undergo surgery due to other conditions such as emphysema, vascular disease and/or heart disease. In these cases, RFA may represent an effective alternative. RFA may also be appropriate for patients with inoperable lung nodules suspicious for lung cancer or spread of disease from other organ sites.
All candidates for RFA must:
During RFA, computed tomography (CT) is used to provide guidance for placement of a small needle in the targeted tumor. Energy is delivered through the needle to create intense heat to ablate, or destroy, the cancerous cells. At Mass General, we can ablate tumors in most patients with peripheral tumors that are smaller than three centimeters. In some cases, we may consider combining external beam radiation and RFA to treat larger tumors. The procedure causes minimal pain, has a very short recovery period and is a viable option for patients with limited lung function.
For patients for whom a chest X-ray or CT scan identifies an abnormality, a diagnosis of lung cancer is usually confirmed via one of three methods:
To determine the extent of tumor, we perform a complete assessment called staging. Patients with lung cancer are first seen at the Multidisciplinary Thoracic Oncology Clinic and are evaluated by thoracic surgeons, oncologists and radiation therapists. A treatment plan is developed that might include surgery, radiation, chemotherapy and/or RFA.
Clinical studies have demonstrated that lung RFA can be an effective treatment for local control of early-stage lung cancer or limited metastatic disease to the lung. We do not recommend this procedure for chronic pain syndromes from spread of tumor to chest wall. RFA, which lasts about two hours, is typically conducted under conscious sedation in our radiology suite. A patient who is deemed a good candidate by a consulting team of physicians to undergo RFA meets with a thoracic radiologist and an interventional radiology nurse to discuss the procedure, possible complications and plan for follow-up.
After the procedure, patients are admitted overnight for monitoring and usually go home the next day. Most patients return quickly to normal activities.
At Mass General, we're committed to following RFA patients closely to gauge their long-term health. We perform follow-up imaging studies at scheduled intervals between one and 24 months. If patients cannot travel to Mass General, the studies can be obtained closer to their home and sent to Mass General for review.
For questions about RFA for lung cancer or to schedule an appointment, please call 617-726-6826.
Mass General has treated early-stage lung cancer with RFA since 2003, making us one of the first hospitals to use the technique for this purpose. The Lung Radiofrequency Ablation Program is a joint effort directed by Michael Lanuti, MD, of the Division of Thoracic Surgery, as well as Jo-Anne Shepard, MD, and Amita Sharma, MBBS, of the Department of Radiology.
We are dedicated to furthering the medical field's understanding of this promising technique. Our experts help lead an annual workshop teaching RFA to radiologists and thoracic surgeons from around the United States. In addition, our division takes part in a national clinical trial studying the outcomes of RFA for medically inoperable stage I lung cancer.
Lung cancer is cancer that usually starts in the lining of the bronchi (the main airways of the lungs), but can also begin in other areas of the respiratory system, including the trachea, bronchioles, or alveoli.
Division of Thoracic Surgery
Back to Top